NCT07129252

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Crinetics Pharmaceuticals Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.

Conditions

• SST2-positive Neuroendocrine Neoplasms
• Neuroendocrine Tumors
• Neuroendocrine Neoplasm

Interventions

Type	Name	Description
DRUG	CRN09682	Study drug CRN09682 intravenously

Timeline

• Start date: 2025-11-26
• Primary completion: 2027-08-01
• Completion: 2029-08-01
• First posted: 2025-08-19
• Last updated: 2026-03-10

Locations

21 sites across 2 countries: United States, Spain

Regulatory

• FDA-regulated drug study